Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and latest CE information More Information
This activity will cover key topics of interest to stakeholders who set practice policy and will be called upon to evaluate and make decisions on issues pertaining to biosimilars.
Choose from the criteria below to find an activity that fits you best.
NOTE: If you attended this CE activity live (via webinar) on October 13, 2016, AND received CE credit (i.e. a pharmacist CE statement with ACPE Universal Activity Number 0221-9999-16-314-L01-P, or Laboratory PACE credit), you are NOT allowed to also receive CE credit for this home-study activity.
Antimicrobial resistant organisms – in particular Gram-negatives – continue to plague the infectious diseases landscape. A number of susceptibility and interpretation criteria have recently been modified by the Clinical and Laboratory Standards Institute (CLSI) that directly pertain to the Gram-negatives. This session will highlight diagnostic and treatment approaches to resistant Gram-negative organisms, with special attention to carbapenem-resistant Enterobacteriaceae (CRE) and extended-spectrum beta-lactamases (ESBLs).
Emily L. Heil, PharmD, BCPS-AQ ID
Assistant Professor - Infectious Diseases
Department of Pharmacy Practice and Science
University of Maryland School of Pharmacy
Barbara L. Zimmer, Ph.D.
Principal Scientist, Scientific Affairs
Beckman Coulter MicroScan
Release Date: 10-13-2016
Expiration Date: 10-13-2017
This CE activity is jointly provided by ProCE, Inc., CLSI, and SIDP. ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-16-314-H01-P has been assigned to this knowledge-based home-study CE activity (initial release date 10-13-16). This CE activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. Successful completion of an online post-test and evaluation at www.ProCE.com is required to receive CE credit. No partial credit will be given.
Clinical and Laboratory Standards Institute is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.â Program. To receive Laboratory PACE credit, please email CLSI Marketing Contact, Shannon Sullivan at firstname.lastname@example.org and request PACE credit for this activity.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and
scientific rigor in all of its continuing education activities. Faculty must disclose
to participants any significant financial interest or affiliation with companies that
manufacture or market products discussed in this activity. Dr. Heil has no relevant
commercial and/or financial relationships to disclose. Dr. Zimmer has no relevant
commercial and/or financial relationships to disclose.
Please note: The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.
This activity is self-funded by SIDP, CLSI, and members of ACCP ID PRN.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.